Ligand Pharmaceuticals Inc.
) Investigational New Drug (IND) application for its Glucagon
Receptor Antagonist program with LGD-6972 was accepted by the
U.S. Food and Drug Administration (FDA) for the treatment of
patients suffering from type II diabetes. The incidence of
diabetes is on a rise across the globe.
Ligand Pharma will commence phase I studies on the candidate
by year end. It is an unpartnered program and the company has
plans to find a partner after phase I study.
Ligand Pharma presented positive pre-clinical data on LGD-6972
at the American Diabetes Association in Jun 2012. The
pre-clinical studies revealed significant glucose lowering
activity by the candidate. The data showed that the highly potent
and selective LGD-6972 inhibits glucagon-induced hyperglycemia in
both rats and monkeys and lowers glucose in a mouse model of type
II diabetes. Studies also showed robust
In Jun 2013, Ligand Pharma had announced positive data from
preclinical studies of LGD-6972, revealing significant glucose
lowering activity in an animal model of type I
Ligand Pharma was in the news earlier this month, when Duavee
received FDA approval for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause and the prevention
of postmenopausal osteoporosis. Duavee was developed by
), and is part of research collaboration with Ligand Pharma. As
per the agreement, Ligand Pharma received milestone payment of
$425,000 for this approval.
Ligand Pharma carries a Zacks Rank #3 (Hold). Currently,
) look more attractive with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
LIGAND PHARMA-B (LGND): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.